<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00783705</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00839</org_study_id>
    <secondary_id>NCI-2009-00839</secondary_id>
    <secondary_id>CDR0000617846</secondary_id>
    <secondary_id>MAY06-8-01</secondary_id>
    <secondary_id>MAY06-8-01</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT00783705</nct_id>
  </id_info>
  <brief_title>Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia</brief_title>
  <official_title>Phase IIb Randomized Comparative Study of the Efficacy and Safety of Myo-inositol Versus Placebo in Smokers With Bronchial Dysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase II trial is studying inositol to see how well it works compared with a
      placebo in preventing lung cancer in current or former smokers with bronchial dysplasia.
      Chemoprevention is the use of certain drugs to keep cancer from forming. The use of inositol
      may prevent lung cancer. It is not yet known whether inositol is more effective than a
      placebo in preventing lung cancer in smokers with bronchial dysplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the efficacy of myo-inositol (inositol) 9 grams by mouth twice a day for 6
      months versus placebo to revert bronchial dysplasia in current/former smokers with or without
      curatively treated Stage 0/I non-small cell lung cancer.

      SECONDARY OBJECTIVES:

      I. To further define the mechanism(s) of action of pharmacological doses of myo-inositol as a
      lung cancer chemopreventive agent by evaluating changes in: the number of dysplastic lesions,
      Ki-67, caspase-3, peroxisome proliferator-activated receptor (PPAR) gamma, cyclin D1, cyclin
      E and vascular endothelial growth factor (VEGF) immunostaining in bronchial biopsies; gene
      expression analysis of ribonucleic acid (RNA) from bronchial brush cells; and changes in
      inflammatory biomarkers (C-reactive protein [CRP], monocyte chemotactic protein-1 [MCP-1],
      myeloid progenitor inhibitory factor-1 [MPIF-1] and L-Selectin) levels in bronchoalveolar
      lavage (BAL) and plasma before and after treatment.

      II. To collect additional safety and adverse event profiles of participants enrolled in both
      intervention arms. III. To establish a biospecimen repository archive for future correlative
      studies.

      OUTLINE: Patients are stratified according to smoking status (current vs former), prior lung
      cancer (yes vs no), and number of dysplastic lesions at baseline (1 vs &gt; 1). Patients are
      randomized to 1 of 2 treatment arms.

      ARM I: Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6
      months in the absence of unacceptable toxicity.

      ARM II: Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6
      months in the absence of unacceptable toxicity.

      Patients undergo white light and autofluorescence bronchoscopy with bronchoalveolar lavage,
      bronchial brushings, and biopsies as well as optical coherence tomography imaging and blood
      sample collection at baseline and after completion of study treatment. Samples are analyzed
      for tissue biomarkers (e.g., PPAR gamma, Ki-67, caspase-3, cyclin D1, cyclin E, and VEGF) by
      immunohistochemistry (IHC); cytokine levels (e.g., CRP, MCP-1, MPIF-1, and L-selectin) by
      ELISA; and gene expression profiles of RNA by microarray.

      After completion of study treatment, patients are followed within 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Response Determined by Change in the Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples on Participant-specific Analysis.</measure>
    <time_frame>From baseline up to 6 months</time_frame>
    <description>The definitions of responses are:
Complete response: regression of all dysplastic lesion (DL) found at baseline to lesions that were no worse than hyperplasia and no new DL that were mild dysplasia or worse; Partial response: regression of some but not all of the DL with no new lesions that are mild dysplasia or worse; Progressive disease: progression of one or more sites by two or more grades or new DL that were mild dysplasia or worse; Stable disease: no complete response, partial response or progression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Response Determined by Change in the Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples on Lesion-specific Analysis.</measure>
    <time_frame>From baseline up to 6 months</time_frame>
    <description>The definitions of responses are:
Complete response: the regression of a dysplastic lesion (DL) of any grade to one classified as being hyperplastic/normal; Progressive disease: appearance of lesions that were classified as mild dysplasia or worse; Stable disease: lesions that are not classified as complete response or progressive disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in the Number of Bronchial Dysplastic Lesions Before and After Treatment</measure>
    <time_frame>From baseline up to 6 months</time_frame>
    <description>The change in the number of bronchial dysplastic lesions is defined as disappearance or appearance of lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in Ki-67 Expression Level in the Bronchial Biopsies With Dysplasia</measure>
    <time_frame>From baseline up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gene Expression Profiles of RNA in Bronchial Brush Cell Samples as Assessed by Microarray</measure>
    <time_frame>From baseline up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Biomarkers Levels (CC-16) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</measure>
    <time_frame>From baseline up to 6 months</time_frame>
    <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Biomarkers Levels (IL-6) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</measure>
    <time_frame>From baseline up to 6 months</time_frame>
    <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Biomarkers Levels (CCL-2) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</measure>
    <time_frame>From baseline up to 6 months</time_frame>
    <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Biomarkers Levels (MPO) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</measure>
    <time_frame>From baseline up to 6 months</time_frame>
    <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Biomarkers Levels (CC18) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</measure>
    <time_frame>From baseline up to 6 months</time_frame>
    <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Biomarkers Levels (SFTPD) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</measure>
    <time_frame>From baseline up to 6 months</time_frame>
    <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Biomarkers Levels (Total Glutathione) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</measure>
    <time_frame>From baseline up to 6 months</time_frame>
    <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Biomarkers Levels (CC-16) in Plasma Samples as Assessed by ELISA</measure>
    <time_frame>From baseline up to 6 months</time_frame>
    <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Biomarkers Levels (CRP) in Plasma Samples as Assessed by ELISA</measure>
    <time_frame>From baseline up to 6 months</time_frame>
    <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Biomarkers Levels (IL-6) in Plasma Samples as Assessed by ELISA</measure>
    <time_frame>From baseline up to 6 months</time_frame>
    <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Biomarkers Levels (CCL-2) in Plasma Samples as Assessed by ELISA</measure>
    <time_frame>From baseline up to 6 months</time_frame>
    <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Biomarkers Levels (MPO) in Plasma Samples as Assessed by ELISA</measure>
    <time_frame>From baseline up to 6 months</time_frame>
    <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Biomarkers Levels (Nitrotyrosine) in Plasma Samples as Assessed by ELISA</measure>
    <time_frame>From baseline up to 6 months</time_frame>
    <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Biomarkers Levels (CC18) in Plasma Samples as Assessed by ELISA</measure>
    <time_frame>From baseline up to 6 months</time_frame>
    <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Biomarkers Levels (SFTPD) in Plasma Samples as Assessed by ELISA</measure>
    <time_frame>From baseline up to 6 months</time_frame>
    <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Squamous Lung Dysplasia</condition>
  <arm_group>
    <arm_group_label>Arm I (inositol)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inositol</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (inositol)</arm_group_label>
    <other_name>myo-inositol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed bronchial dysplasia in ≥ 1 site AND meets one of the
             following criteria:

               -  Current or former smoker with ≥ a 30 pack-year smoking history and no history of
                  lung cancer

               -  Stage 0 or I non-small cell lung cancer (NSCLC) curatively treated by surgery
                  (local ablation or resection), adjuvant chemotherapy, or radiotherapy with a ≥ 30
                  pack-year smoking history

                    -  At least 6 months since prior surgery, adjuvant chemotherapy, or
                       radiotherapy

          -  No current evidence of lung cancer by CT scan

               -  No non-calcified lung nodules ≥ 10 mm diameter on spiral CT scan unless cancer is
                  ruled out by PET/CT scan or by biopsy

          -  ECOG performance status 0-1

          -  Hemoglobin normal

          -  Leukocyte count ≥ 3,000/mm³

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  Alkaline phosphatase ≤ 1.5 times ULN

          -  ALT and AST ≤ 1.5 times ULN

          -  BUN ≤ 1.5 times ULN

          -  Chloride ≤ 1.5 times ULN

          -  Total CO_2 ≤ 1.5 times ULN

          -  Sodium ≤ 1.5 times ULN

          -  Calcium ≤ 1.5 times ULN

          -  Potassium ≤ 1.5 times ULN

          -  Phosphorus ≤ 1.5 times ULN

          -  Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 30mL/min

          -  Fasting blood glucose normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No cancer within the past 3 years except stage 0 or I NSCLC, nonmelanomatous skin
             cancer, localized prostate cancer, carcinoma in situ of the cervix, or superficial
             bladder cancer that was treated &gt; 6 months ago

          -  No concurrent uncontrolled illness including, but not limited to, any of the
             following:

               -  Ongoing or active infection

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia

               -  Severe chronic obstructive pulmonary disease requiring supplemental oxygen

               -  Uncontrolled hypertension

               -  Psychiatric illness or social situation that would limit compliance with study
                  requirements

          -  No schizophrenia or bipolar disorder

          -  No diabetes

          -  No requirement for supplemental oxygen (continuous or intermittent)

          -  SaO_2 ≥ 90% on room air

          -  No history of allergic reactions attributed to inositol

          -  No history of allergies to any ingredient in the study agent or placebo

          -  No other concurrent investigational agents

          -  At least 7 days since prior anticoagulant use (e.g., coumadin or heparin)

          -  More than 6 months since prior participation in another chemoprevention clinical trial

          -  No prior pneumonectomy

          -  No prior solid organ transplantation

          -  No concurrent lithium, carbamazepine, or valproate

          -  No concurrent use of other natural health products containing inositol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Limburg</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Veterans Administration Medical Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108-5128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA-Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2008</study_first_submitted>
  <study_first_submitted_qc>October 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2008</study_first_posted>
  <results_first_submitted>April 29, 2015</results_first_submitted>
  <results_first_submitted_qc>July 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 25, 2015</results_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>448 subjects were pre-registered through 3 Cancer Prevention Network (CPN) member organizations from 2008 to 2013.</recruitment_details>
      <pre_assignment_details>363 subjects were excluded from pre-assignment: 342 ineligible via bronchoscopy, 3 participant decision, 13 lab values out of range, 1 screening time line issue and 4 suspicious of cancer.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A (Myo-inositol)</title>
          <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Arm B (Placebo)</title>
          <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A (Myo-inositol)</title>
          <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Arm B (Placebo)</title>
          <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" lower_limit="45.0" upper_limit="75.0"/>
                    <measurement group_id="B2" value="58.0" lower_limit="46.0" upper_limit="79.0"/>
                    <measurement group_id="B3" value="58.0" lower_limit="45.0" upper_limit="79.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index, kg/m^2</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.2" lower_limit="21.1" upper_limit="36.3"/>
                    <measurement group_id="B2" value="26.0" lower_limit="21.0" upper_limit="35.2"/>
                    <measurement group_id="B3" value="26.5" lower_limit="21.0" upper_limit="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior NSAID (nonsteroidal anti-inflammatory drugs) Use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Intake</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1 or fewer drinks per day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-3 drinks per day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 or more drinks per day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dysplastic Lesions Identified</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1 Dysplastic lesion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1 Dysplastic lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mucosal Biopsies Obtained</title>
          <units>biopsies</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.0" lower_limit="1.0" upper_limit="14.0"/>
                    <measurement group_id="B2" value="7.0" lower_limit="1.0" upper_limit="14.0"/>
                    <measurement group_id="B3" value="7.0" lower_limit="1.0" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Most Advanced Histology</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mild dysplasia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate dysplasia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe dysplasia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Response Determined by Change in the Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples on Participant-specific Analysis.</title>
        <description>The definitions of responses are:
Complete response: regression of all dysplastic lesion (DL) found at baseline to lesions that were no worse than hyperplasia and no new DL that were mild dysplasia or worse; Partial response: regression of some but not all of the DL with no new lesions that are mild dysplasia or worse; Progressive disease: progression of one or more sites by two or more grades or new DL that were mild dysplasia or worse; Stable disease: no complete response, partial response or progression.</description>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response Determined by Change in the Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples on Participant-specific Analysis.</title>
          <description>The definitions of responses are:
Complete response: regression of all dysplastic lesion (DL) found at baseline to lesions that were no worse than hyperplasia and no new DL that were mild dysplasia or worse; Partial response: regression of some but not all of the DL with no new lesions that are mild dysplasia or worse; Progressive disease: progression of one or more sites by two or more grades or new DL that were mild dysplasia or worse; Stable disease: no complete response, partial response or progression.</description>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3"/>
                    <measurement group_id="O2" value="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8"/>
                    <measurement group_id="O2" value="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Response Determined by Change in the Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples on Lesion-specific Analysis.</title>
        <description>The definitions of responses are:
Complete response: the regression of a dysplastic lesion (DL) of any grade to one classified as being hyperplastic/normal; Progressive disease: appearance of lesions that were classified as mild dysplasia or worse; Stable disease: lesions that are not classified as complete response or progressive disease</description>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response Determined by Change in the Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples on Lesion-specific Analysis.</title>
          <description>The definitions of responses are:
Complete response: the regression of a dysplastic lesion (DL) of any grade to one classified as being hyperplastic/normal; Progressive disease: appearance of lesions that were classified as mild dysplasia or worse; Stable disease: lesions that are not classified as complete response or progressive disease</description>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                    <measurement group_id="O2" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                    <measurement group_id="O2" value="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Generalized estimating equation model on lesions (progressive disease vs. complete response/stable disease) was used to account for intra-patient correlation in the lesion-specific analysis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.39</p_value>
            <method>Generalized estimating equation model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in the Number of Bronchial Dysplastic Lesions Before and After Treatment</title>
        <description>The change in the number of bronchial dysplastic lesions is defined as disappearance or appearance of lesions.</description>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with lesions biopsied.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in the Number of Bronchial Dysplastic Lesions Before and After Treatment</title>
          <description>The change in the number of bronchial dysplastic lesions is defined as disappearance or appearance of lesions.</description>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with lesions biopsied.</population>
          <units>percentage change in number of lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.5" spread="116.1"/>
                    <measurement group_id="O2" value="-50.0" spread="115.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change in Ki-67 Expression Level in the Bronchial Biopsies With Dysplasia</title>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with lesions biopsied.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in Ki-67 Expression Level in the Bronchial Biopsies With Dysplasia</title>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with lesions biopsied.</population>
          <units>percentage of Ki67 expression level</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.8" spread="105.3"/>
                    <measurement group_id="O2" value="-6.2" spread="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Gene Expression Profiles of RNA in Bronchial Brush Cell Samples as Assessed by Microarray</title>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>Data were not collected due to a study team decision not to analyze this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gene Expression Profiles of RNA in Bronchial Brush Cell Samples as Assessed by Microarray</title>
          <population>Data were not collected due to a study team decision not to analyze this endpoint.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Biomarkers Levels (CC-16) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</title>
        <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with bronchoalveolar lavage samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Biomarkers Levels (CC-16) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</title>
          <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with bronchoalveolar lavage samples available</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.96" lower_limit="-127.56" upper_limit="52.26"/>
                    <measurement group_id="O2" value="-54.32" lower_limit="-144.65" upper_limit="140.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the median difference in biomarker CC-16 level between arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Wilcoxon Rank-Sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Biomarkers Levels (IL-6) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</title>
        <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with bronchoalveolar lavage samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Biomarkers Levels (IL-6) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</title>
          <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with bronchoalveolar lavage samples available</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" lower_limit="-2.78" upper_limit="0.34"/>
                    <measurement group_id="O2" value="-0.27" lower_limit="-1.54" upper_limit="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the median difference in biomarker IL-6 level between arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon Rank-Sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Biomarkers Levels (CCL-2) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</title>
        <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with bronchoalveolar lavage samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Biomarkers Levels (CCL-2) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</title>
          <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with bronchoalveolar lavage samples available</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.25" lower_limit="-44.32" upper_limit="8.62"/>
                    <measurement group_id="O2" value="9.41" lower_limit="-52.58" upper_limit="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the median difference in biomarker CCL-2 level between arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Wilcoxon Rank-Sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Biomarkers Levels (MPO) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</title>
        <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with bronchoalveolar lavage samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Biomarkers Levels (MPO) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</title>
          <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with bronchoalveolar lavage samples available</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.46" lower_limit="-8.17" upper_limit="2.77"/>
                    <measurement group_id="O2" value="-1.15" lower_limit="-8.43" upper_limit="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the median difference in biomarker MPO level between arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Wilcoxon Rank-Sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Biomarkers Levels (CC18) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</title>
        <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with bronchoalveolar lavage samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Biomarkers Levels (CC18) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</title>
          <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with bronchoalveolar lavage samples available</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-121.47" lower_limit="-1234.7" upper_limit="1122.9"/>
                    <measurement group_id="O2" value="10.70" lower_limit="-684.95" upper_limit="683.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the median difference in biomarker CC18 level between arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.63</p_value>
            <method>Wilcoxon Rank-Sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Biomarkers Levels (SFTPD) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</title>
        <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with bronchoalveolar lavage samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Biomarkers Levels (SFTPD) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</title>
          <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with bronchoalveolar lavage samples available</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.39" lower_limit="-47.12" upper_limit="5.72"/>
                    <measurement group_id="O2" value="7.21" lower_limit="-7.62" upper_limit="23.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the median difference in biomarker SFTPD level between arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Wilcoxon Rank-Sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Biomarkers Levels (Total Glutathione) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</title>
        <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with bronchoalveolar lavage samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Biomarkers Levels (Total Glutathione) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)</title>
          <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with bronchoalveolar lavage samples available</population>
          <units>umol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" lower_limit="-1.98" upper_limit="0.48"/>
                    <measurement group_id="O2" value="-0.56" lower_limit="-1.13" upper_limit="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the median difference in biomarker Total Glutathione level between arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Wilcoxon Rank-Sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Biomarkers Levels (CC-16) in Plasma Samples as Assessed by ELISA</title>
        <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with plasma samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Biomarkers Levels (CC-16) in Plasma Samples as Assessed by ELISA</title>
          <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with plasma samples available</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" lower_limit="-0.82" upper_limit="0.92"/>
                    <measurement group_id="O2" value="-0.58" lower_limit="-1.71" upper_limit="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the median difference in biomarker CC-16 level between arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>Wilcoxon Rank-Sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Biomarkers Levels (CRP) in Plasma Samples as Assessed by ELISA</title>
        <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with plasma samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Biomarkers Levels (CRP) in Plasma Samples as Assessed by ELISA</title>
          <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with plasma samples available</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.18" lower_limit="-248.55" upper_limit="744.31"/>
                    <measurement group_id="O2" value="-74.11" lower_limit="-752.24" upper_limit="412.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the median difference in biomarker CRP level between arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.80</p_value>
            <method>Wilcoxon Rank-Sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Biomarkers Levels (IL-6) in Plasma Samples as Assessed by ELISA</title>
        <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with plasma samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Biomarkers Levels (IL-6) in Plasma Samples as Assessed by ELISA</title>
          <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with plasma samples available</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="-0.74" upper_limit="0.46"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.55" upper_limit="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the median difference in biomarker IL-6 level between arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Wilcoxon Rank-Sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Biomarkers Levels (CCL-2) in Plasma Samples as Assessed by ELISA</title>
        <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with plasma samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Biomarkers Levels (CCL-2) in Plasma Samples as Assessed by ELISA</title>
          <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with plasma samples available</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" lower_limit="-35.08" upper_limit="29.56"/>
                    <measurement group_id="O2" value="9.08" lower_limit="-5.53" upper_limit="44.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the median difference in biomarker CCL-2 level between arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Wilcoxon Rank-Sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Biomarkers Levels (MPO) in Plasma Samples as Assessed by ELISA</title>
        <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with plasma samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Biomarkers Levels (MPO) in Plasma Samples as Assessed by ELISA</title>
          <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with plasma samples available</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="-2.05" upper_limit="2.17"/>
                    <measurement group_id="O2" value="0.09" lower_limit="-1.57" upper_limit="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the median difference in biomarker MPO level between arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Wilcoxon Rank-Sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Biomarkers Levels (Nitrotyrosine) in Plasma Samples as Assessed by ELISA</title>
        <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with plasma samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Biomarkers Levels (Nitrotyrosine) in Plasma Samples as Assessed by ELISA</title>
          <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with plasma samples available</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="-2.84" upper_limit="4.68"/>
                    <measurement group_id="O2" value="0.88" lower_limit="-1.7" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the median difference in biomarker Nitrotyrosine level between arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.91</p_value>
            <method>Wilcoxon Rank-Sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Biomarkers Levels (CC18) in Plasma Samples as Assessed by ELISA</title>
        <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with plasma samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Biomarkers Levels (CC18) in Plasma Samples as Assessed by ELISA</title>
          <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with plasma samples available</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="-0.6" upper_limit="3.19"/>
                    <measurement group_id="O2" value="-0.16" lower_limit="-2.42" upper_limit="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the median difference in biomarker CC18 level between arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>Wilcoxon Rank-Sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Biomarkers Levels (SFTPD) in Plasma Samples as Assessed by ELISA</title>
        <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
        <time_frame>From baseline up to 6 months</time_frame>
        <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with plasma samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Myo-inositol)</title>
            <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Biomarkers Levels (SFTPD) in Plasma Samples as Assessed by ELISA</title>
          <description>The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&amp;D Systems), interleukin-6 (IL-6, R&amp;D Systems), and CCL-2 (R&amp;D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&amp;D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&amp;D Systems) and CC18 (R&amp;D Systems).</description>
          <population>The analysis population included the participants who received study intervention and completed both the pre- and post-intervention bronchoscopy with plasma samples available</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" lower_limit="-0.93" upper_limit="1.51"/>
                    <measurement group_id="O2" value="-0.22" lower_limit="-1.26" upper_limit="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the median difference in biomarker SFTPD level between arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.52</p_value>
            <method>Wilcoxon Rank-Sum</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events reported on all participants. The adverse events: cardiac disorders, blood disorders, gastrointestinal disorder and etc. which are simply repeating their organ system names were referred to other, specify category of the adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A (Myo-inositol)</title>
          <description>Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="E2">
          <title>Arm B (Placebo)</title>
          <description>Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAEV3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAEV3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Middle ear inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vitreous hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="26" subjects_affected="18" subjects_at_risk="44"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>General symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Peripheral nerve infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Serum sodium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Joint disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased cervical spine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Muscle weakness upper limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin urine positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Urogenital disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Penile pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Prostatic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Reproductive tract disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Laryngeal edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul J. Limburg, M.D., M.P.H.</name_or_title>
      <organization>Mayo Clinic Rochester</organization>
      <phone>507-284-2511</phone>
      <email>limburg.paul@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

